Tofacitinib also strongly suppressed IFN in the blood.[33,34] However, 1 study reported that the therapeutic effects of tofacitinib on ILD and rash were limited.[35] Similarly, tofacitinib failed to halt disease progression in a recent study.[36]. Here, IFNA1 is linked to interstitial lung disease.